FEV1 % predicted: relative change from baseline · adults and children with CF
1 finding from 1 review
Time to next exacerbation · adults and children with CF
1 finding from 1 review
Participants hospitalised for respiratory exacerbation · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events mild adverse events · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
1 finding from 1 review
QoL · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum microbiology · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inflammatory markers · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection
Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).
1 finding from 1 review
Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).
1 finding from 1 review
Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
QoL · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
FEV1 % predicted · adults and children with cystic fibrosis
Summary of findings: β‐carotene showed no clear difference in respiratory function absolute FEV1 % predicted compared with placebo (low certainty).
1 finding from 1 review
Sputum microbiology · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
Inflammatory markers · children (12 or over) and adults with cystic fibrosis and lung infection
1 finding from 1 review
Pulmonary exacerbations · children (12 or over) and young adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 (% predicted): mean change from baseline · children (12 or over) and young adults with cystic fibrosis
Summary of findings: nitric oxide showed no clear difference in respiratory function mean change in FEV1 % predicted from baseline compared with placebo (low certainty).
1 finding from 1 review
Adverse events · children (12 or over) and young adults with cystic fibrosis
It is very uncertain whether summary of findings: nitric oxide changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
QoL · children (12 or over) and young adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found